On June 3, 2026 IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, reported the publication of a review article titled: "Harnessing γδ T cells through engineering and combination therapies" in the journal Nature Communications. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors and hematologic cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
γδ T cells differ from conventional alpha-beta T cells through their ability to recognize stress-associated signals independent of major histocompatibility complex (MHC) restriction. This potentially solves problems associated with therapeutic development and enables them to target tumors that evade traditional immune responses. The publication reviews emerging engineering strategies, including CAR-γδ T cells, cytokine-armored γδ T cells, TCE approaches, and antibody-secreting γδ T cells, as well as combination approaches involving checkpoint inhibitors, chemotherapy, cytokines, and bispecific antibodies.
"We are pleased Nature Communications published this review highlighting the rapid progress and growing momentum across the γδ T cell field," said Lawrence Lamb, CSO and scientific co-founder of IN8bio. "The publication highlights the unique biological properties of γδ T cells and their potential to address important limitations associated with current immunotherapy approaches, particularly in difficult-to-treat solid tumors. We believe advances in engineering, manufacturing, and combination strategies are continuing to expand the therapeutic potential of γδ T cells across oncology and autoimmune diseases."
The publication also highlights the potential for allogeneic "off-the-shelf" γδ T cell therapies due to the cells’ lack of graft-versus-host disease (GvHD)-associated alloreactivity, as well as growing clinical evidence supporting γδ T cell therapies across hematologic malignancies and solid tumors, including glioblastoma.
In addition, the review discusses how γδ T cells may function as orchestrators of immune surveillance through their ability to recognize heterogeneous tumor-associated stress signals and potentially overcome mechanisms of immune escape commonly observed in advanced cancers.
This review was authored by an international group of five highly respected oncologists and immunologists including Lawrence Lamb, PhD and IN8bio’s Scientific Advisory Board (SAB) member Jonathan Fisher, BM, PhD, MRCPCH from University College London. There are an increasing number of actively recruiting γδ T cell clinical trials globally, reflecting growing academic and industry interest in the platform across cancer and autoimmune diseases.
(Press release, In8bio, JUN 3, 2026, View Source [SID1234666406])